- Home
- YMM vs MRNA Comparison
YMM vs MRNA Comparison
Compare YMM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMM | MRNA |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 11.5B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | YMM | MRNA |
|---|---|---|
| Price | $8.80 | $52.57 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 12 |
| Target Price | $12.00 | ★ $33.00 |
| AVG Volume (30 Days) | 6.5M | ★ 9.0M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $11.40 | $8.28 |
| Revenue Next Year | N/A | $16.53 |
| P/E Ratio | $18.30 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $8.75 | $22.28 |
| 52 Week High | $14.07 | $59.55 |
Technical Indicators
Market Signals| Indicator | YMM | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 54.70 |
| Support Level | N/A | $48.09 |
| Resistance Level | $9.73 | $55.20 |
| Average True Range (ATR) | 0.28 | 3.56 |
| MACD | -0.01 | -0.30 |
| Stochastic Oscillator | 10.48 | 33.94 |
Price Performance
Historical ComparisonAbout YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.